On April 22, the Food and Drug Administration (FDA) inspected LifeStart Fertility Center in Agoura Hills regarding human cellular, tissue, and gene therapies, according to data posted on the FDA’s website.
The final report stated that LifeStart Fertility Center was not required to make any changes to its organizational operations.
The FDA regularly inspects facilities nationwide to verify whether workplaces and their products comply with FDA laws and regulations meant to safeguard public health. The agency releases inspection outcomes to the public.
As outlined on its website, the FDA is a federal agency responsible for ensuring the safety and quality of human and animal drugs, biological products, medical supplies, and tobacco products by overseeing their production and distribution.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
